

Metfoam 500 SR

Name of the Product: Metfoam 500 SR

Composition: Each uncoated sustained-release tablet contains Metformin Hydrochloride IP 500 mg

Dosage Form: Sustained Release Tablet

Description:

Metfoam 500 SR contains Metformin Hydrochloride, a biguanide oral antidiabetic agent, in a sustained-release form that provides controlled drug release to maintain stable plasma levels. It is primarily used in the management of type 2 diabetes mellitus in patients whose blood sugar is not adequately controlled by diet and exercise alone. Metformin improves glucose tolerance and lowers both basal and postprandial blood glucose levels without causing significant hypoglycemia when used as monotherapy.

Indications:

Indicated for the treatment of type 2 diabetes mellitus, particularly in overweight adults, when dietary management and physical activity alone do not result in adequate glycemic control. It can be used as monotherapy or in combination with other oral antidiabetic agents or insulin.

Mechanism of Action:

Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and enhances insulin sensitivity by increasing peripheral glucose uptake and utilization. It does not increase insulin secretion and does not typically cause hypoglycemia when used alone.

Dosage and Administration:

The usual starting dose is one tablet once daily, preferably with the evening meal. The dosage may be gradually increased under medical supervision based on blood glucose response. Tablets must be swallowed whole without crushing or chewing. Maximum recommended dose is 2000 mg per day in divided doses.

Contraindications:

Contraindicated in patients with hypersensitivity to Metformin, severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in conditions associated with tissue hypoxia such as congestive heart failure or respiratory failure.

Warnings and Precautions:

Lactic acidosis is a rare but serious complication and may occur due to accumulation of Metformin. It is essential to monitor renal function regularly, especially in elderly patients. Avoid use in patients with liver disease, and temporarily discontinue in cases requiring surgery or radiologic procedures involving iodinated contrast media. Alcohol intake should be minimized due to the increased risk of lactic acidosis.

Adverse Effects:

Common side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, flatulence, and abdominal discomfort. These effects are usually transient and diminish as therapy

continues. Long-term use may impair vitamin B12 absorption. Lactic acidosis is a rare but potentially fatal side effect requiring immediate discontinuation.

Storage:

Store in a cool and dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

Schedule: Schedule H Prescription Drug – To be sold by retail on the prescription of a Registered Medical Practitioner only.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for